Morgan Stanley Aptevo Therapeutics Inc. Transaction History

Morgan Stanley

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$0.17 - $0.38 $1,932 - $4,320	11,370 New	11,370 $2,000
Q4 2023 Feb 13, 2024	BUY	$0.17 - $0.38 $60 - $135	357 Added 3.24%	11,370 $2,000
Q1 2023 May 15, 2023	SELL	$1.74 - $2.54 $522 - $762	-300 Reduced 2.65%	11,013 $22,000
Q4 2022 Feb 14, 2023	SELL	$2.0 - $138.16 $15,002 - $1.04 Million	-7,501 Reduced 39.87%	11,313 $26,000
Q3 2022 Nov 14, 2022	SELL	$3.12 - $142.56 $10,788 - $492,972	-3,458 Reduced 15.53%	18,814 $57,000
Q2 2022 Oct 27, 2022	SELL	$3.26 - $6.3 $93,966 - $181,591	-28,824 Reduced 56.41%	22,272 $80,000
Q2 2022 Aug 15, 2022	SELL	$3.26 - $6.3 $93,966 - $181,591	-28,824 Reduced 56.41%	22,272 $80,000
Q1 2022 Oct 27, 2022	BUY	$4.48 - $8.42 $129,131 - $242,698	28,824 Added 129.42%	51,096 $300,000
Q1 2022 May 13, 2022	SELL	$4.48 - $8.42 $273,544 - $514,116	-61,059 Reduced 54.44%	51,096 $300,000
Q4 2021 Feb 14, 2022	BUY	$6.48 - $17.49 $655,302 - $1.77 Million	101,127 Added 917.0%	112,155 $883,000
Q3 2021 Nov 15, 2021	BUY	$15.01 - $22.16 $165,530 - $244,380	11,028 New	11,028 $170,000

Ticker APVO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,090,640
Market Cap $22.4M
Description
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelo...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.